Investors Shouldn't Be Too Comfortable With Acotec Scientific Holdings' (HKG:6669) Earnings

Investors were disappointed with Acotec Scientific Holdings Limited's (HKG:6669) earnings, despite the strong profit numbers. We did some digging and found some worrying underlying problems.

earnings-and-revenue-history
SEHK:6669 Earnings and Revenue History September 30th 2025
Advertisement

The Impact Of Unusual Items On Profit

Importantly, our data indicates that Acotec Scientific Holdings' profit received a boost of CN¥10m in unusual items, over the last year. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And that's as you'd expect, given these boosts are described as 'unusual'. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Acotec Scientific Holdings' Profit Performance

Arguably, Acotec Scientific Holdings' statutory earnings have been distorted by unusual items boosting profit. Therefore, it seems possible to us that Acotec Scientific Holdings' true underlying earnings power is actually less than its statutory profit. But the happy news is that, while acknowledging we have to look beyond the statutory numbers, those numbers are still improving, with EPS growing at a very high rate over the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. While it's really important to consider how well a company's statutory earnings represent its true earnings power, it's also worth taking a look at what analysts are forecasting for the future. So feel free to check out our free graph representing analyst forecasts.

This note has only looked at a single factor that sheds light on the nature of Acotec Scientific Holdings' profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SEHK:6669

Acotec Scientific Holdings

Operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally.

Flawless balance sheet with solid track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
CUE logo
Lou_Basenese on Cue Biopharma ·

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

Fair Value:US$7057.9% undervalued
20 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
HE
HedgeY
ASTS logo
HedgeY on AST SpaceMobile ·

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets

Fair Value:US$17044.9% undervalued
40 users have followed this narrative
0 users have commented on this narrative
12 users have liked this narrative
FU
ONTO logo
FundamentalFlow on Onto Innovation ·

Onto Innovation: The Advanced Packaging Chokepoint 51.3% undervalued intrinsic discount

Fair Value:US$38033.4% undervalued
26 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7447.4% undervalued
58 users have followed this narrative
0 users have commented on this narrative
15 users have liked this narrative

Updated Narratives

TI
3REN logo
TimLee on 3REN Berhad ·

3REN Berhad Is Powering the Semiconductor Ecosystem and Smart Manufacturing

Fair Value:RM 0.6841.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
CHEEDING logo
Anthony_Lee on Cheeding Holdings Berhad ·

Cheeding: The Hidden Beneficiary of Malaysia’s Power Grid Expansion

Fair Value:RM 1.242.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
FU
KRMN logo
FundamentalFlow on Karman Holdings ·

KRMN — Karman Space & Defense: Down 58% from Peak, Is the Market Mispricing a Hypergrowth Defense Compounder?

Fair Value:US$105.653.2% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7447.4% undervalued
58 users have followed this narrative
0 users have commented on this narrative
15 users have liked this narrative
CL
Clive_Thompson
TTWO logo
Clive_Thompson on Take-Two Interactive Software ·

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Fair Value:US$276.9722.6% undervalued
57 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
NI
niteco
HON logo
niteco on Honeywell International ·

Honeywell - The Demand-Side of the AI Infrastructure

Fair Value:US$320.1933.2% undervalued
48 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative